SEMA4D in cancer diagnosis, detection and treatment

Details SEMA4D in cancer diagnosis, detection and treatment SEMA4D in cancer diagnosis, detection and treatment

2011-04-05

2011-04-05

Aeder, Sean E (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S007100

Reexamination Certificate

active

07919246

ABSTRACT:
This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the SEM A4D gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the SEMA4D gene.

REFERENCES:
patent: 7171311 (2007-01-01), Dai et al.
patent: 97/17368 (1997-05-01), None
patent: 03/057146 (2003-07-01), None
patent: 2005/031001 (2005-04-01), None
Hall et al (PNAS, Oct. 1996, 93: 11780-11785) teaches.
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Alberts et al. (Molecular Biology of the Cell, 3rd edition, 1994, p. 465).
Greenbaum et al. (Genome Biology, 2003, vol. 4, Issue 9, pp. 117.1-117.8).
Dorfman et al (American Journal of Pathology, Jul. 1998, 153(1): 255-262).
Basile et al., “Class IV semaphorins promote anglogenesls by stimulating Rho-initiated pathways through piexin-B.”Cancer Res64(15):5212-5224 (2004).
Basile et al., “Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis.”Proc. Natl. Acad. Sci.U.S.A. 103(24):9017-9022 (2006).
Conrotto et al., “Interplay between scatter factor receptors and B plexins controls invasive growth.”Oncogene23(30):5131-5137 (2004).
Deaglio et al., “CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival.”Blood105(8): 3042-3050 (2005).
Dorfman et al., “The leukocyte semaphorin CD100 is expressed in most T-cell, but few B-cell, non-Hodgkin's lymphomas.”Am. J. Pathol153(1):255-262 (1998).
Elhabazi et al., “Biological activity of soluble CD100. I. The extracellular region of CD100 is released from the furface of T lymphocytes by regulated proteopysis.”J. Immunol166(7):4341-4347 (2001).
Glordano et al., “The semaphorin 4D receptor controls invasive growth by coupling with Met.”Nat. Cell. Biol.4(9):720-724 (2002).
Granziero et al., “CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes.”Blood101(5):1962-1969 (2003).
Hansen et al., “Genetic profile of insertion mutations in mouse leukemias and lymphomas.”Genome Res.10(2):237-243 (2000).
Herold et al., “Activation signals are delivered through two distinct epitopes of CD100, a unique 150 kDa human lymphocyte surface structure previously defined by BB18 mAb.”Int. Immunol.7(1):1-8 (1995).
Joosten et al., “Phenotyping of Evi1. Evi11/Cb2, and Evi12 transformed leukemias isolated from a novel panel of cas-Br-M murine leukemia virus-infected mice.”Virology268(2):308-318 (2000).
Kim et al., “Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas.”J. Virol.77(3):2056-2062 (2003).
Kumanogoh et al., “Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling.”Immunity13(5):621-631 (2000).
Li et al., “Leukaermia disease genes: large-scale cloning and pathway predictions,”Nat. Genet.23(3):348-353 (1999).
Mikkers and Berns, “Retroviral Insertional mutagenesis: lagging cancer pathways.”Adv. Cancer Res88:53-99 (2003).
Sørensen et al., “Amplification and sequence analysis of DNA flanking integrated proviruses by a simple two-step polymerase chain reaction method.”J. Virol.67(12):7118-7124 (1993).
Sørensen et al., “Sequence tags of provirus integration sites in DNAs of tumors induced by the murine retrovirus SL3-3.”J. Virol.70(6):4063-4070 (1996).
Sørensen et al., “Sint1, a common integration site in SL3-3-induced T-cell lymphomas, harbors a putative proto-oncogene with homology to the septin gene family.”J. Virol.74(5):2161-2166 (2000).
Vikis et al., “The semaphorin receptor plexin-B1 specifically interacts with active Rac in a ligand-dependent manner.”Proc. Natl. Acad. Sci.U.S.A. 97(23):12457-12462 (2000).
Yamada et al., “Identification of semaphorin E as a non-MDR drug resistance gene of human cancers.”Proc. Natl. Acad. Sci.U.S.A. 26(94):14713-14718 (1997).
Accession No. AAC50810, Nov. 29, 2010.
Accession No. AAH54500, Nov. 29, 2010.
Accession No. BCO54500, Nov. 29, 2010.
Accession No. BX648216, Nov. 29, 2010.
Accession No. NM—006378, Nov. 29, 2010.
Accession No. NP—006369, Nov. 29, 2010.
Accession No. Q92854, Nov. 29, 2010.
Accession No. U60800, Nov. 29, 2010.

Affiliated with

Also associated with

Rating

SEMA4D in cancer diagnosis, detection and treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with SEMA4D in cancer diagnosis, detection and treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SEMA4D in cancer diagnosis, detection and treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2630495